With over 6.46 million Cameco Corp. (CCJ) shares trading Tuesday and a closing price of $44.73 on the day, the dollar volume was approximately $288.8 million. The shares have shown a positive half year performance of 43.32% and its price on 01/09/24 gained nearly 4.73%. Currently, there are 432.52M common shares owned by the public and among those 431.94M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 12 analysts who have offered their price forecasts for CCJ have a consensus price objective of $70.82. The analysts have set the share’s price value over the next 12 months at a high of $76.00 and a low of $64.98. The average price target is 15.4% above its recent price level and an upside to the estimated low will see the stock gain 31.16% over that period. But an upside of 41.14% will see the stock hit the forecast high price target while median target price for the stock is $71.00.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The top 3 mutual fund holders in Cameco Corp. are Global X Uranium ETF, American Funds Capital World Grow, and Fidelity Canadian Growth Company. Global X Uranium ETF owns 13.45 million shares of the company’s stock, all valued at over $617.68 million. American Funds Capital World Grow sold 8699.0 shares to see its total holdings shrink to 11.44 million shares valued at over $525.2 million and representing 2.64% of the shares outstanding. Fidelity Canadian Growth Company now owns shares totaling to 1.74% of the shares outstanding.
Shares of Cameco Corp. (NYSE: CCJ) opened at $42.47, down -$0.24 from a prior closing price of $42.71. However, the script later moved the day high at 45.12, up 4.73%. The company’s stock has a 5-day price change of 6.40% and 19.73% over the past three months. CCJ shares are trading 3.78% year to date (YTD), with the 12-month market performance up to 83.02% higher. It has a 12-month low price of $23.69 and touched a high of $46.95 over the same period. CCJ has an average intraday trading volume of 4.85 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.94%, 2.95%, and 27.87% respectively.
Institutional ownership of Cameco Corp. (NYSE: CCJ) shares accounts for 77.31% of the company’s 432.52M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $19.41B and a beta (3y monthly) value of 0.95. The stock’s trailing 12-month PE ratio is 98.68, while the earnings-per-share (ttm) stands at $0.45. The company has a PEG of 2.03 and a Quick Ratio of 3.31 with the debt-to-equity ratio at 0.16. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.69% over the week and 3.25% over the month.
Analysts forecast that Cameco Corp. (CCJ) will achieve an EPS of $0.17 for the current quarter, $0.24 for the next quarter and $1.13 for 2024. The lowest estimate earnings-per-share for the quarter is $0.07 while analysts give the company a high EPS estimate of $0.31. Comparatively, EPS for the current quarter was $0.07 a year ago. Earnings per share for the fiscal year are expected to increase by 157.51%, and 92.49% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 12 brokerage firm advisors rate Cameco Corp. (CCJ) as a “Strong Buy” at a consensus score of 1.42. Specifically, 9 Wall Street analysts polled rate the stock as a buy, while 2 of the 12 advise that investors “hold,” and 0 rated it as a “Sell.”
